Zebra Technologies (ZBRA) fell 8.3% to $331.22 on November 3, 2026, despite third-quarter sales up 22.3% and a raised full-year outlook. The drop extends a 13.2% five-day slide and leaves the shares oversold. The weekly uptrend is intact, so the balance of evidence leans positive, but only weakly. The stock is lagging both the market and its sector, and the math from a breakout does not reach 3 to 1.
Why it matters
The quarter was strong on every headline measure. According to the SEC filing, net sales were $1,614 million, up 22.3% from a year earlier. Net income was $164 million, or $3.43 a share. Non-GAAP earnings were $4.95 a share, and adjusted EBITDA rose to $349 million, a 21.6% margin. The company also raised its full-year outlook. Growth at that pace, with margins held and guidance higher, is what a bull case needs from a report.
The market sold it anyway. CNBC noted that ZBRA was down more than 6% premarket even though results beat estimates, and the regular session was worse. Volume ran 180.6% above its 20-day average, so this was a heavy exit rather than a thin air pocket. The most consistent explanation is what was already in the price. The shares had gained 45.9% in six months and hit a 52-week high near $391 on October 21. A beat and a raise were largely expected. The news provided does not say what specifically disappointed, so that explanation is an inference, not a reported fact.
Most of the five-day drop is not about the market. ZBRA is down 13.2% over five days, against 2.1% for the S&P 500 and 7.1% for the technology sector fund XLK. The market explains a small slice. The sector explains a larger one, since XLK is also down 11.9% over a month and tech was already under pressure before this report. The stock's own share is the remaining 6.2 points below XLK. Today the pattern is starker: XLK rose 1.1% and SPY 0.2% while ZBRA fell 8.3%, so today's loss belongs to the stock alone.
No articles in the debate feed make a case against ZBRA, so the argument is visible mainly in two places. The first is the analysts. Fifteen cover the stock, the consensus is buy, and the mean price target is $414.85, with targets from $350 to $460. Even the lowest target is above today's price, which sits 20.2% below the mean. The second is the price action. A sell-off on a beat and a raise, after a run of this size, is the market saying that good results were not enough at $391. Both are true at once, and the report does not settle which one wins.
What the evidence says
The long-term thesis is intact but has taken a hit. The price is above its 40-week average, the 200-day average sits at $280.96, well below the price, and the stock is 14.8% ahead of the S&P 500 over 200 days. The stock is in a pullback inside a larger uptrend. It is 15.3% below its October 21 peak, below its 10-week average and below the 50-day average at $366.75, but still 66.2% above its 52-week low.
For the next two to six weeks, the balance of evidence leans positive, with low conviction: 1 point out of 4. The one thing that clearly points up is that a pullback inside a weekly uptrend has reached oversold, with the 14-day RSI at 27.5. Two things point the other way. Over 50 days ZBRA is lagging the S&P 500 by 8.1% and XLK by 2.9%, and a stock trailing both its market and its sector is going against the trend. Those readings are why the score is not higher.
The strongest case against the positive reading is that this is not a quiet dip. The stock fell 13.2% in five days on volume near three times normal, it has lost its shorter-term averages, and it is underperforming a sector that is itself falling. Oversold conditions can persist, and a decline driven by a re-rating can run further than a decline driven by a bad quarter. It does not tip the balance because the weekly uptrend is untouched, the stock is still well above its 200-day average, and the business just reported accelerating sales with a higher outlook. It is the reason conviction stays low.
Levels that matter
The structure holds above $325, a round number just under the current price, and the first crack comes on a break below it. Below that, $300 is the next round-number support, followed by the 200-day average at $280.96. The trend ends below $275.62, a swing zone from earlier in the advance, which is why a weekly close under it matters more than any one-day move. The next swing zone is at $241.16.
On the upside, the breakout level is a daily close above $350 on volume above the 20-day average. That would be the first sign that buyers are back. From $350 the math is a stop at $320.92, which is $325 minus a quarter of the 14-day ATR of $16.31. The first target is the 50-day average at $366.75, which gives 0.6 to 1. The second is the 52-week high at $391, which gives 1.4 to 1. The math does not reach 3 to 1. It would need a target above the $414.85 mean analyst target, well past the 52-week high, so the payoff is thin relative to the risk at these levels.
What would change the picture
A weekly close below $275.62 would end the uptrend and turn the evidence negative, because it would break the last swing zone beneath the 200-day average. The non-price fact most likely to cause that is a cut to the full-year outlook raised today, or any sign that demand behind the 22.3% sales growth is fading. Either would undercut the one clear strength in the story, which is the business itself.
What to watch
- Next earnings: the report landed today, and the next date is not in the data. The number that matters is sales growth against the 22.3% just reported, together with whether the raised full-year outlook holds.
- Sector: XLK is down 11.9% over a month, so moves in technology can push ZBRA before any company news does. A sector bounce would help, and further weakness would add to the pressure.
- Price levels: $325 as the first line of support, and a close above $350 on above-average volume as the first sign of recovery.
- Valuation: at $331.22 the stock trades 20.2% below the $414.85 mean target and below even the lowest target of $350. The consensus is that the shares are worth more, but the market has just disagreed.